Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.70 |
| ▸ | DRD2 | P14416 | 10/20 | 0.70 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205715 | 0.83 | HTR2A (0.70) | HTR2ADRD2HTR1A | |
| SCHEMBL6187784 | 0.82 | HTR2A (0.70) | HTR2ADRD2HTR7DRD4SIGMAR1 | |
| SCHEMBL6188843 | 0.79 | HTR2A (0.56) | HTR2ADRD2HTR7HTR1AHTR6 | |
| SCHEMBL6185028 | 0.77 | HTR2A (0.64) | HTR2ADRD2HTR7HTR1AHTR6 | |
| SCHEMBL5795751 | 0.74 | HTR2A (0.54) | HTR2ADRD2HTR7DRD4SIGMAR1 | |
| SCHEMBL5767235 | 0.74 | HTR2A (0.54) | HTR2ADRD2HTR7DRD4SIGMAR1 | |
| SCHEMBL6186885 | 0.72 | HTR2A (0.57) | HTR2ADRD2HTR7DRD4SIGMAR1 | |
| SCHEMBL6206072 | 0.71 | HTR2A (0.68) | HTR2ADRD2HTR1A | |
| SCHEMBL6186888 | 0.70 | HTR2A (0.56) | HTR2ADRD2HTR7DRD4SIGMAR1 | |
| SCHEMBL6107521 | 0.69 | HTR2A (0.51) | HTR2ADRD2HTR7DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546145-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029048-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | DAVIS JAMIE MARIE (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | HTR2C, CNR1, HTR2A | HTR2A 3/4885DRD2 4/4885HTR7 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.